Market Summary
USD14.08-0.33
Market Closed-2.29%
CERT Stock Price
CERT RSI Chart
CERT Valuation
CERT Price/Sales (Trailing)
CERT Profitability
CERT Fundamentals
CERT Revenue
CERT Earnings
Price Action
52 Week Range
10.6024.96
(Low)(High)
Last 7 days
-0.1%
Last 30 days
-12%
Last 90 days
-19.6%
Trailing 12 Months
7.8%
CERT Financial Health
CERT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CERT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-11 | Pedersen Leif E | sold | -747,870 | 14.6 | -51,224 | president, chief commercal off |
2023-08-22 | BROSHY ERAN | bought | 75,950 | 15.8 | 4,807 | - |
2023-08-21 | BROSHY ERAN | bought | 3,107 | 16.1 | 193 | - |
2023-08-01 | SHERMAN NICOLETTE D | sold (taxes) | -20,579 | 19.47 | -1,057 | chief human resources officer |
2023-06-30 | Aspbury Robert | sold (taxes) | -15,679 | 18.19 | -862 | president, simcyp |
2023-06-05 | SMITH PATRICK F | sold | -411,691 | 21.55 | -19,104 | president, integrated drug dev |
2023-05-23 | BROSHY ERAN | acquired | - | - | 9,360 | - |
2023-05-23 | Crane Rosemary A | acquired | - | - | 9,324 | - |
2023-05-17 | WALSH MATTHEW M | acquired | - | - | 9,067 | - |
2023-05-17 | CASHMAN JAMES E III | acquired | - | - | 9,067 | - |
Which funds bought or sold CERT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 10.48 | -146,000 | 746,000 | -% |
2023-08-25 | Yarbrough Capital, LLC | unchanged | - | -76,429 | 235,892 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 7.97 | -599,230 | 2,647,950 | -% |
2023-08-21 | BOKF, NA | sold off | -100 | -313 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -55.39 | -403,725 | 205,366 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 63.28 | 122,000 | 641,000 | 0.01% |
2023-08-16 | Sunbelt Securities, Inc. | added | 78.28 | 2,114 | 7,921 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -6.38 | -2,349,010 | 5,668,990 | -% |
2023-08-16 | CASTLEARK MANAGEMENT LLC | sold off | -100 | -5,174,490 | - | -% |
2023-08-15 | Parkside Financial Bank & Trust | added | 6.05 | -17,207 | 69,253 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Certara
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 6.80% | 10,850,994 | SC 13G/A | |
| Feb 09, 2023 | eqt avatar parent l.p. | 0% | 0 | SC 13G/A | |
| Jan 18, 2023 | baillie gifford & co | 6.40% | 10,223,809 | SC 13G/A | |
| Dec 16, 2022 | arsenal capital partners iii lp | 2.2% | 3,559,745 | SC 13D | |
| Feb 14, 2022 | eqt avatar parent l.p. | 23.5% | 37,458,939 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 5.92% | 9,310,068 | SC 13G |
Recent SEC filings of Certara
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 11, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 23, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 10-Q | Quarterly Report | |
| Aug 02, 2023 | 4 | Insider Trading | |
| Jul 03, 2023 | 4 | Insider Trading |
Certara News
Returns for CERT
Cumulative Returns on CERT
Risks for CERT
What is the probability of a big loss on CERT?
91.8%
Probability that Certara stock will be more than 20% underwater in next one year
91.8%
Probability that Certara stock will be more than 30% underwater in next one year.
57.5%
Probability that Certara stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CERT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Certara was unfortunately bought at previous high price.
Drawdowns
Financials for Certara
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Revenue | 2.2% | 352 | 344 | 336 | 324 | 314 | 301 | 286 | 275 | 262 | 253 | 244 | 239 | 237 | 230 | 209 |
| Operating Expenses | -1.3% | 174 | 176 | 171 | 170 | 175 | 168 | 161 | 202 | 185 | 175 | 167 | 112 | 108 | 109 | 109 |
| S&GA Expenses | 3.4% | 30.00 | 29.00 | 27.00 | 26.00 | 25.00 | 23.00 | 20.00 | 24.00 | 22.00 | 20.00 | 19.00 | 12.00 | 11.00 | 12.00 | 11.00 |
| R&D Expenses | 0.5% | 30.00 | 30.00 | 28.00 | 28.00 | 26.00 | 23.00 | 20.00 | 24.00 | 23.00 | 21.00 | 20.00 | 12.00 | 12.00 | 12.00 | 12.00 |
| EBITDA | -100.0% | - | 39.00 | 38.00 | 32.00 | 19.00 | 17.00 | 16.00 | -41.82 | -34.12 | 38.00 | 42.00 | 42.00 | 47.00 | 36.00 | - |
| EBITDA Margin | -100.0% | - | 0.11* | 0.11* | 0.10* | 0.06* | 0.06* | 0.05* | -0.15* | -0.13* | 0.15* | 0.18* | 0.18* | 0.20* | 0.16* | - |
| Interest Expenses | 8.9% | 22.00 | 20.00 | 18.00 | 16.00 | 14.00 | 16.00 | 17.00 | 19.00 | 22.00 | 22.00 | 25.00 | 26.00 | 28.00 | 27.00 | 28.00 |
| Earnings Before Taxes | 32.0% | 23.00 | 17.00 | 19.00 | 15.00 | 3.00 | -1.21 | -3.37 | -63.14 | -58.17 | -50.27 | -50.18 | 13.00 | 16.00 | 7.00 | -9.15 |
| EBT Margin | -100.0% | - | 0.05* | 0.06* | 0.05* | 0.01* | 0.00* | -0.01* | -0.23* | -0.22* | 0.05* | 0.05* | 0.05* | 0.07* | 0.03* | - |
| Net Income | 38.2% | 19.00 | 14.00 | 15.00 | -4.14 | -9.84 | -12.11 | -13.27 | -58.01 | -55.02 | -49.39 | -49.40 | 7.00 | 8.00 | 4.00 | -8.93 |
| Net Income Margin | -100.0% | - | 0.04* | 0.04* | -0.01* | -0.03* | -0.04* | -0.05* | -0.21* | -0.21* | 0.03* | 0.03* | 0.03* | 0.03* | 0.02* | - |
| Free Cashflow | -100.0% | - | 91.00 | 91.00 | 76.00 | 72.00 | 64.00 | 59.00 | 51.00 | 47.00 | 37.00 | 42.00 | 42.00 | 32.00 | 33.00 | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
| Assets | 0.3% | 1,572 | 1,567 | 1,573 | 1,509 | 1,502 | 1,507 | 1,512 | 1,415 | 1,265 | 1,263 | 1,269 |
| Current Assets | 1.4% | 353 | 348 | 342 | 305 | 286 | 275 | 275 | 505 | 345 | 348 | 347 |
| Cash Equivalents | 0.4% | 245 | 244 | 237 | 211 | 198 | 185 | 187 | 418 | 270 | 273 | 273 |
| Net PPE | -4.8% | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 |
| Goodwill | 0.4% | 722 | 719 | 718 | 697 | 701 | 705 | 3.00 | 181 | 524 | 519 | 519 |
| Liabilities | -1.4% | 475 | 482 | 493 | 454 | 453 | 459 | 470 | 443 | 431 | 435 | 447 |
| Current Liabilities | 9.7% | 103 | 94.00 | 103 | 77.00 | 82.00 | 82.00 | 92.00 | 70.00 | 59.00 | 63.00 | 75.00 |
| LT Debt, Current | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 5.00 | 5.00 |
| LT Debt, Non Current | -0.2% | 289 | 290 | 290 | 290 | 291 | 291 | 292 | 292 | 293 | 294 | 294 |
| Shareholder's Equity | 1.1% | 1,097 | 1,085 | 1,080 | 1,054 | 1,048 | 1,048 | 1,042 | 971 | 835 | 827 | 822 |
| Retained Earnings | 7.9% | -54.81 | -59.51 | -60.87 | -70.05 | -73.98 | -73.39 | -75.60 | -65.90 | -64.14 | -61.29 | -62.34 |
| Additional Paid-In Capital | 0.3% | 1,162 | 1,159 | 1,150 | 1,144 | 1,137 | 1,127 | 1,120 | 1,039 | 897 | 890 | 885 |
| Shares Outstanding | 0.0% | 160 | 160 | 160 | 160 | 156 | 156 | 160 | 149 | 147 | 147 | 153 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Cashflow From Operations | -5.6% | 87.00 | 93.00 | 93.00 | 78.00 | 74.00 | 65.00 | 60.00 | 52.00 | 48.00 | 41.00 | 45.00 | 43.00 | 33.00 | 35.00 | 38.00 |
| Cashflow From Investing | -38.8% | -30.38 | -21.89 | -27.84 | -264 | -263 | -275 | -269 | -22.00 | -21.37 | -9.06 | -8.61 | -9.61 | -10.48 | -12.04 | -9.52 |
| Cashflow From Financing | -43.2% | -9.58 | -6.69 | -7.36 | -10.04 | 124 | 123 | 123 | 359 | 186 | 188 | 208 | -32.14 | 34.00 | 76.00 | -8.49 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 4.00 | 0.00 | - | 1.00 |
CERT Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenues | $ 90,450 | $ 82,760 | $ 180,751 | $ 164,311 |
| Cost of revenues | 36,224 | 35,194 | 71,080 | 67,983 |
| Operating expenses: | ||||
| Sales and marketing | 8,111 | 7,121 | 16,113 | 13,232 |
| Research and development | 7,888 | 7,741 | 17,175 | 15,289 |
| General and administrative | 14,245 | 17,778 | 34,017 | 36,117 |
| Intangible asset amortization | 10,582 | 10,355 | 21,117 | 20,504 |
| Depreciation and amortization expense | 361 | 422 | 772 | 904 |
| Total operating expenses | 41,187 | 43,417 | 89,194 | 86,046 |
| Income from operations | 13,039 | 4,149 | 20,477 | 10,282 |
| Other income (expenses): | ||||
| Interest expense | (5,668) | (3,879) | (11,143) | (7,107) |
| Net other income | 1,010 | 2,521 | 1,516 | 3,362 |
| Total other expenses | (4,658) | (1,358) | (9,627) | (3,745) |
| Income before income taxes | 8,381 | 2,791 | 10,850 | 6,537 |
| Provision for income taxes | 3,675 | 3,380 | 4,786 | 4,916 |
| Net income (loss) | 4,706 | (589) | 6,064 | 1,621 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation adjustment | 1,815 | (7,520) | 4,416 | (10,704) |
| Change in fair value from interest rate swap, net of tax | 2,332 | 848 | 641 | 912 |
| Total other comprehensive income (loss) | 4,147 | (6,672) | 5,057 | (9,792) |
| Comprehensive income (loss) | $ 8,853 | $ (7,261) | $ 11,121 | $ (8,171) |
| Net income (loss) per share attributable to common stockholders: | ||||
| Basic (in dollar per share) | $ 0.03 | $ (0.00) | $ 0.04 | $ 0.01 |
| Diluted (in dollar per share) | $ 0.03 | $ 0.00 | $ 0.04 | $ 0.01 |
| Weighted average common shares outstanding: | ||||
| Basic (in shares) | 158,955,822 | 156,478,724 | 158,568,575 | 156,209,335 |
| Diluted (in shares) | 159,906,972 | 156,478,724 | 159,817,688 | 159,293,362 |
CERT Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 245,190 | $ 236,586 |
| Accounts receivable, net of allowance for credit losses of $460 and $1,250, respectively | 83,952 | 82,584 |
| Restricted cash | 3,020 | 3,102 |
| Prepaid expenses and other current assets | 20,882 | 19,980 |
| Total current assets | 353,044 | 342,252 |
| Other assets: | ||
| Property and equipment, net | 2,206 | 2,400 |
| Operating lease right-of-use assets | 12,326 | 14,427 |
| Goodwill | 721,853 | 717,743 |
| Intangible assets, net of accumulated amortization of $244,974 and $217,705, respectively | 473,805 | 486,782 |
| Deferred income taxes | 3,703 | 3,703 |
| Other long-term assets | 5,283 | 5,615 |
| Total assets | 1,572,220 | 1,572,922 |
| Current liabilities: | ||
| Accounts payable | 3,789 | 7,533 |
| Accrued expenses | 38,654 | 35,403 |
| Current portion of deferred revenue | 52,788 | 52,209 |
| Current portion of long-term debt | 3,020 | 3,020 |
| Other current liabilities | 4,645 | 4,993 |
| Total current liabilities | 102,896 | 103,158 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 2,056 | 2,815 |
| Deferred income taxes | 54,677 | 65,046 |
| Operating lease liabilities, net of current portion | 8,285 | 10,133 |
| Long-term debt, net of current portion and debt discount | 289,104 | 289,988 |
| Other long-term liabilities | 18,028 | 22,121 |
| Total liabilities | 475,046 | 493,261 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Preferred shares, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 0 | 0 |
| Common shares, $0.01 par value, 600,000,000 shares authorized, 160,171,493 and 159,676,150 shares issued as of June 30, 2023 and December 31, 2022, respectively; 159,777,284 and 159,525,943 shares outstanding as of June 30, 2023 and December 31, 2022, respectively | 1,601 | 1,596 |
| Additional paid-in capital | 1,162,317 | 1,150,168 |
| Accumulated deficit | (54,809) | (60,873) |
| Accumulated other comprehensive loss | (3,173) | (8,230) |
| Treasury stock at cost, 394,209 and 150,207 shares at June 30, 2023 and December 31, 2022, respectively | (8,762) | (3,000) |
| Total stockholders’ equity | 1,097,174 | 1,079,661 |
| Total liabilities and stockholders’ equity | $ 1,572,220 | $ 1,572,922 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.